Drug Profile


Alternative Names: NE-10064; Stedicor

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer Allergan; Blue Ash Therapeutics; Mitsubishi Tanabe Pharma Corporation; Procter & Gamble
  • Class Class III antiarrhythmics; Imidazolidines; Piperazines
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ventricular arrhythmias
  • No development reported Arrhythmias; Atrial fibrillation; Atrial flutter; Postmyocardial infarction; Supraventricular arrhythmias

Most Recent Events

  • 11 Aug 2015 Azimilide is still in phase III development for Ventricular arrhythmias in USA
  • 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top